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Objectives This study sought to examine the safety and efficacy of laser-assisted lead extraction and the indications, out-
comes, and risk factors in a large series of consecutive patients.
Background The need for lead extraction has been increasing in direct relationship to the increased numbers of cardiovascu-
lar implantable electronic devices.
Methods Consecutive patients undergoing transvenous laser-assisted lead extraction at 13 centers were included.
Results Between January 2004 and December 2007, 1,449 consecutive patients underwent laser-assisted lead extraction of
2,405 leads (20 to 270 procedures/site). Median implantation duration was 82.1 months (0.4 to 356.8 months).
Leads were completely removed 96.5% of the time, with a 97.7% clinical success rate whereby clinical goals associ-
ated with the indication for lead removal were achieved. Failure to achieve clinical success was associated with body
mass index25 kg/m2 and low extraction volume centers. Procedural failure was higher in leads implanted for10 years
and when performed in low volume centers. Major adverse events in 20 patients were directly related to the proce-
dure (1.4%) including 4 deaths (0.28%). Major adverse effects were associated with patients with a body mass index
25 kg/m2. Overall all-cause in-hospital mortality was 1.86%; 4.3% when associated with endocarditis, 7.9% when associ-
ated with endocarditis and diabetes, and 12.4% when associated with endocarditis and creatinine2.0. Indicators of all-
cause in-hospital mortality were pocket infections, device-related endocarditis, diabetes, and creatinine2.0.
Conclusions Lead extraction employing laser sheaths is highly successful with a low procedural complication rate. Total mortality
is substantially increased with pocket infections or device-related endocarditis, particularly in the setting of diabetes,
renal insufficiency, or body mass index25 kg/m2. Centers with smaller case volumes tended to have a lower rate of
successful extraction. (J Am Coll Cardiol 2010;55:579–86) © 2010 by the American College of Cardiology Foundation
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Laser Lead Extraction February 9, 2010:579–86The need for percutaneous trans-
venous lead extraction has been
increasingly required in direct re-
lationship to the increased num-
bers of cardiovascular implant-
able electronic devices (CIEDs)
and is expected to continue to
grow.
Unfortunately, the compo-
nents of the CIED, the leads and
pulse generators, do not function
perpetually. As the population
and the CIED ages, components
of the system need to be ex-
tracted for a variety of reasons
including infection, lead mal-
unction, venous stenosis, and occlusion, as well as safety
lerts. Perceptions of lead extraction safety and effectiveness
nd the outcomes of patients undergoing transvenous lead
xtraction have been based on early, relatively small trials,
nd a voluntary reporting of outcomes in a multicenter
xtraction registry (1–3). Historically, the perceived risk of
xtraction has limited the referral and performance of this
rocedure to patients with life-threatening situations (Class
indications). Growing physician experience and the de-
elopment of newer tools have influenced the outcomes of
ransvenous lead extraction and thereby indications.
The goal of this study was to determine the contemporary
afety and efficacy of excimer laser-assisted lead extraction,
n a large series of consecutive patients who presented to 13
enters. In addition, the indications for extraction, out-
omes, and risk factors for complications and mortality were
etermined.
ethods
onsecutive patients who underwent laser-assisted lead
xtraction (LALE) using the CVX-300 (Spectranetics,
olorado Springs, Colorado) laser system and the SLS II
Spectranetics) laser sheath between January 1, 2004, and
ecember 31, 2007, were included. Patients were excluded
f another nonlaser, nontraction device was used in the same
rocedure.
Data was collected at 13 sites in the U.S. and Canada. A
re-study, self-reported questionnaire to determine lead
xtraction caseloads over the previous 4-year period and
ractice type (academic vs. private practice) was used to
nsure a wide range of settings and experience. Centers were
ivided into 3 groups (small60 cases, mid60 and 130
ases, and large130 cases). The protocol was reviewed and
pproved by the institutional review board of each center.
Definitions published in 2000 in the North American
ociety of Pacing and Electrophysiology (NASPE) (now
he Heart Rhythm Society) guidance document on trans-
enous lead extraction were used to calculate the safety and
Abbreviations
and Acronyms
BMI  body mass index
CIED  cardiovascular
implantable electronic
device
DRE  device-related
endocarditis
LALE  laser-assisted
lead extraction
MAE  major adverse
event
NASPE  North American
Society of Pacing and
Electrophysiologyffectiveness of the extraction procedure and the rates of drocedural (radiographic) and clinical success and compli-
ations (4).
Indications for lead extraction were classified as: 1) pocket
nfection; 2) device-related endocarditis (DRE); 3) pain;
) venous stenosis or occlusion; 5) functional but aban-
oned; or 6) nonfunctional leads.
Pocket infection was defined as erythema with or without
urulent discharge, device erosion, fat necrosis, and/or
dherence of device to the skin, which may be accompanied
y pain. All other infections in the presence of a CIED were
onsidered device-related endocarditis. This included all
ersistent bacteremia or sepsis in the absence of another
dentifiable source or vegetations on the leads or valves in
he presence of a device. Pain was defined as a lead
xtraction done to relieve pain associated with the device
nd leads without suspected infection. Extraction for non-
unctional lead status was defined as being related to a
echanical lead failure established on the basis of clinically
ignificant alterations in pacing, sensing, lead impedance, or
nappropriate tachycardia therapies.
Leads may be extracted when upgrading 1 system to
nother such as pacemaker to an implantable cardioverter-
efibrillator or a pacemaker/implantable cardioverter-
efibrillator to a cardiac resynchronization device when
psilateral venous occlusion or stenosis is encountered. In
ddition, concern regarding possible interference with an-
ther device, treatment of malignancy, or causing another
edical condition were indications for extraction. Potential
uture venous occlusion and infection due to superfluous
bandoned leads were also reasons for extraction of the
unctional lead. If venous stenosis or occlusion was present,
hen the extraction indication was so designated, but if the
oncern was for abandoning leads, then the indication was
esignated a “functional abandoned lead.”
aser extraction. Laser sheaths were employed in all cases
hen the leads could not be explanted by simple traction.
he extraction procedure has been described in detail
reviously (3). In brief, the lead was prepared by inserting a
ocking stylet into the inner coil lumen when possible. A
uture is then tied onto the insulation and the locking stylet.
he laser sheath was then advanced over the lead. Laser
pplication was performed at binding sites and advanced
radually from 1 binding site to another until the tip of the
ead was reached. Once abutting the myocardium, a com-
ination of traction and countertraction was performed and
he lead was freed.
The procedural and clinical success definitions employed
n this study were as defined in the NASPE 2000 Policy
tatement (4). Procedural success was defined as complete
r partial and is identified for each lead extracted. Complete
uccess was defined as the ability to remove “all lead material
rom the vascular space.” Partial success was defined as
removal of all but a small portion of the lead; this may be
he electrode, 4 cm or less of conductor coil, and/or
nsulation, or the latter two combined.” Procedural failure is
efined as “abandoning a significant length of lead (more
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February 9, 2010:579–86 Laser Lead Extractionhan 4 cm) after attempted removal.” Clinical success,
efined as achievement of “all clinical goals associated with
he indication for lead removal,” was identified only once for
ach procedure. At a minimum, the clinical goals included:
resolution of the clinical indication for lead removal” and
absence of major complications and control of pacing
tatus.” Clinical failure was defined as the “inability to
chieve all of the clinical goals” outlined herein (4).
ata collection procedures. In each institution, a patient
dentification log was generated that included all lead
xtractions. Each patient was given a unique identifier. Each
edical record was reviewed from admission to discharge
nd an initial data collection form was completed by a
rained data collector. To reduce potential bias, a blinded
rained second data collector then independently reviewed
he medical record and completed a second data collection
orm on a random selection of10% of the medical records
nd 100% of the medical records of patients who had
ustained an adverse event during hospitalization.
Definitions for major and minor complications (adverse
vents) are described in the NASPE 2000 Policy Statement
4). A major adverse event (MAE) was defined as “any
omplication related to the procedure that required proce-
ural intervention or transfusion to prevent death, threat to
ife, or any complication related to the procedure that
esulted in death or serious harm to bodily function or
tructure.” A minor adverse event was “any complication
elated to the procedure that required medical or minor
rocedural intervention to remedy or prolonged hospital
tay or limited the patient’s function but did not threaten
ife, cause death or cause serious harm to bodily function or
tructure.”
The clinical events committee reviewed all adverse events.
he clinical events committee members were blinded to all
atient and site identifiers. The events were reviewed and
djudicated as major or minor and categorical relationships
ere defined in relation to: 1) LALE procedure; 2) another
rocedure; or 3) pre-existing conditions. Within the pre-
xisting conditions category, specific medical conditions or
reatments were further evaluated for relationship to the
vent, including: sepsis, use of anticoagulants, renal insuf-
ciency, and loss of biventricular pacing.
ata analysis. Data analyses were conducted using the
AS system, version 9.1 (SAS Institute Inc., Cary, North
arolina). Descriptive statistics for continuous variables
ere expressed as mean, median, standard deviation, and
anges. Discrete variables were expressed as frequencies and
ercentages. Proportions, such as implant duration category
ersus procedural/clinical success and procedural MAE
ersus center size, were compared using the chi-square test.
isher exact test was used for small cell sizes (5 cases).
edian implant duration of lead time for MAE versus
hose leads without MAE was assessed using the Wilcoxon
ank sum test, due to lack of normality. All tests of
ignificance were 2-sided, with statistical significance set at
 0.05. In addition, surrogate modeling was performed Hor the duration of lead implant in patients who had more
han 1 lead extracted. The longest duration of any lead with
ALE was then used to represent the individual patient.
Multivariate logistic regression analysis was performed to
etermine predictors within 6 categories: 1) clinical failure;
) procedural failure; 3) procedural MAE; 4) all-cause
n-hospital mortality; 5) all-cause in-hospital mortality in
he infected population (DRE  pocket infection); and
) all-cause in-hospital mortality in the DRE population.
redictors were selected from the previously conducted
nivariate analyses where the coefficients were significant.
dditional covariate relationships were analyzed, interac-
ion/confounding testing was also performed to produce a
redictive model at p  0.05. Model-building strategy and
oodness of fit test was derived from Hosmer and Leme-
how test (5). The candidate variables used in the models
ncluded: 1) type of lead (pacer or implantable cardioverter-
efibrillator); 2) duration of the lead implantation;
) volume of procedures at the center; 4) body mass index
ize 25 (underweight and normal weight); 5) renal insuf-
ciency defined as a pre-procedure serum creatinine 2.0
g/dl; 6) diabetes; 7) endocarditis; 8) pocket infection;
) age 65 years; and 10) sex.
esults
uring the period of January 1, 2004, to December 31,
007, a total of 1,449 patients underwent LALE in the 13
enters (see the Online Appendix for centers and cases per
enter). Physicians had a mean of 11.4  6.32 years (range
.0 to 19.0 years, median 13.0 years) of experience with lead
xtraction and a mean of 7.87  3.56 years (range 2.0 to
3.0 years, median 8.0 years) of experience with LALE at
he study completion. In these patients, extraction was
ttempted on 2,405 leads including 1,684 pacemaker (70%),
03 defibrillator (29.2%), and 18 (0.7%) unknown leads.
ost leads were active fixation leads (1,226 active, 832
assive, 347 unknown). Patient characteristics can be seen
n Table 1. The mean age of patients was 63.4 17.1 years;
1.8% of the patients were male, and the mean left ventric-
lar ejection fraction was 37.7  16.6%. Diabetes mellitus
as present in 403 (27.8%) patients, and 728 (50.2%)
emographics and Risk FactorsTable 1 Demographics and Risk Factors
Age, yrs 63.4 17.06
Sex, % male (n  1,041) 71.8
Ejection fraction, % 37.7 16.57
Diabetes mellitus* 403 (28.1%)
CAD† 728 (50.1%)
ICD 703 (29.2%)
NYHA functional class III‡ 145 (41.6%)
alues are mean SD, %, or n (%). There were a total of 1,449 patients and 2,405 leads. *A total
f 1,433 patients had data regarding history of diabetes mellitus available. †A total of 1,435
atients had data regarding history of CAD available. ‡A total of 349 patients had data regarding
YHA functional class available.
CAD  coronary artery disease; ICD  implantable cardioverter-defibrillator; NYHA  New York
eart Association.
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Laser Lead Extraction February 9, 2010:579–86atients had coronary artery disease. Among the 349 pa-
ients with a reported New York Heart Association func-
ional class, 41.6% had class III heart failure symptoms at
he time of the extraction. Most leads were extracted from
he right ventricle (63.5%, n  1,528) and right atrium
32%, n 769); 11 (0.5%) were located in the superior vena
ava, 70 (2.9%) were coronary sinus leads, and 27 (1.1%)
ere unknown. The median implant duration was 82.1
onths (range 0.4 to 356.8). The number of patients at each
ite ranged from 20 to 270 patients.
The indications for lead extraction in the study are
resented in Table 2. The most common indication for
xtraction was infection (56.9%, n  825) with 29.2% (n 
23) related to DRE and 27.7% (n  402) due to pocket
nfections. Venous stenosis or occlusion was noted in 4.5%
n  65), and pain at the device implant or lead insertion
ite accounted for 0.8% (n  12). Nonfunctional leads
epresented 26.6% (n  386) and functional but abandoned
eads represented 11.1% (n  161). Of the functional and
onfunctional leads extracted, the Medtronic Sprint Fidelis
ead, with or without documented failure, contributed 2.5%
n  61) of the patients with 100% clinical and procedural
uccess.
Overall, 2,322 leads (96.5%) were completely and 56
eads (2.3%) were partially removed with a combined success
ate of 98.8%. Clinical success was achieved in 1,416
atients (97.7%) (Table 3).
The multivariate model indicated that failure to achieve
linical success was associated (model likelihood ratio of p
.0128) with patient body mass index (BMI) 25 kg/m2
nd when the extraction center volume was 60 cases over
period of 4 years. In contrast, the multivariate model
ndicated that failure to achieve procedural success was
ssociated (model likelihood ratio of p  0.0005) with lead
mplantation durations of 10 years and when the extrac-
ion center volume of extraction was60 cases over a period
f 4 years.
rocedural adverse events. All-cause adverse events col-
ected during the hospitalization included 63 MAEs in 58
atients (4.0%), and 27 minor adverse events in 26 patients
1.8%). Of these, 24 major events in 20 patients (1.4%) and
minor events in 8 patients (0.6%) were directly related to
he lead extraction portion of the procedure. In addition, a
otal of 27 patients (1.86%) died during the index hospital-
ndications for Lead Extraction (n  1,449)Table 2 Indications for Lead Extraction (n  1,449)
Infection 825 (56.9%)
DRE: sepsis/endocarditis/bacteremia 423 (29.2%)
Pocket infection/erosion—no bacteremia 402 (27.7%)
Functional, abandoned leads 386 (26.6%)
Nonfunctional leads 161 (11.1%)
Venous stenosis/occlusion 65 (4.5%)
Chronic pain at device or insertion site 12 (0.8%)
RE  device-related endocarditis.zation of which 4 (0.28%) were deemed to be directlyelated to the extraction procedure. Table 4 lists all major
nd minor adverse events noted in the study. The multivar-
ate model indicated that only patients with a BMI 25
g/m2 (p  0.0132) were more likely to experience a
rocedural MAE related to the lead extraction procedure.
rocedural MAE were not significantly associated with any
ther parameter as listed in Table 5.
n-hospital mortality and comorbidities. Patients requir-
ng transvenous lead extraction have overlapping comorbidi-
ies that increase the risk for death during their hospitaliza-
ion. The multivariate model indicates that patients with
reatinine 2.0 mg/dl, diabetes mellitus, BMI 25 kg/m2,
nd infection (pocket infection or DRE) were all at in-
reased risk of death (model likelihood ratio of p 0.0001).
Although mortality was higher in patients with DRE
ompared with patients with pocket infection, this differ-
nce was not statistically significant 4.35% versus 1.7% (p
.06). The overall demographic comparisons of patients
ith infection versus those without infection are listed in
able 6.
There were 825 (56.9%) patients with device-related
nfections, 423 with DRE and 402 with pocket infections.
he infected patients were more likely to be older men, who
ad slightly better ejection fractions. In addition, they were
ore likely to be diabetic (35.0% vs. 18.3%, p  0.0001)
nd have renal insufficiency with a creatinine 2.0 mg/dl
16.0% vs. 6.4%, p  0.0001). The all-cause in-hospital
ortality in infected patients was also increased (3% vs.
.3%, p  0.0001, odds ratio [OR]: 9.7), but there was no
ssociation with clinical success rate or procedure-related
AE rates (Table 6). Separately, the DRE patient cohort
n-hospital mortality was much higher (4.3%, 18 of 423)
ompared with the pocket infection patient cohort (1.7%, 7
f 402). When diabetes or renal insufficiency was addition-
lly present, the DRE patients fared more poorly. Among
hose DRE patients with concomitant diabetes, 7.9% (13 of
64) died versus 2% (5 of 253) without a history of diabetes
p 0.0075, OR: 4.3). The odds of an in-hospital mortality
ere 7.0 times higher in DRE patients with renal insuffi-
iency (creatinine 2.0 mg/dl) than among those with
RE and creatinine 2.0 mg/dl (12.4% vs. 2.0%, p 
.0001).
rocedural and Clinical SuccessTable 3 Procedural and Clinical Success
Complete (Per Lead) 2,322 (96.5%)
Partial 56 (2.3%)
Combined complete and partial 2,378 (98.8%)
Failure 27 (1.1%)
Total 2,405
Clinical success (per patient)
Success 1,416 (97.7%)
Failure 33 (2.3%)Total 1,449
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February 9, 2010:579–86 Laser Lead Extractioniscussion
e evaluated the safety and efficacy of laser-assisted lead
xtractions using current indications based on the NASPE
000 Policy Statement. Since the initially reported experi-
nces, which employed earlier editions of the extraction
ools and largely represented the learning curve with laser
xtraction techniques, this consecutive patient experience
epresents the mature contemporary practice in multiple
enters with varying degrees of experience. Each of the
arlier studies addressed the efficacy and safety of the initial
odels of laser sheath. In this study, the modified SLS II
heath was employed, which has improved mechanical
roperties enhancing advancement over the lead. Compared
ith previous studies, LALE was associated with higher
rocedural and clinical success and a similar procedural-
elated major complication rate, but a lower procedural
ortality rate. When BMI was 25 kg/m2, it predicted
rocedural MAE and clinical failure, whereas renal insuffi-
iency, diabetes, BMI 25 kg/m2, and presence of pocket
Adverse EventsTable 4 Adverse Events
All-cause adverse events
Death
Bleeding requiring transfusion
Hematoma requiring drainage
Cardiac avulsion or tear requiring thoracotomy, pericardio
Vascular tear requiring thoracotomy, pericardiocentesis, c
requiring surgical repair
Thrombosis of implant vein resulting in medical intervent
Arrhythmia requiring cardioversion
Hemothorax from any source requiring transfusion
Pulmonary embolism not requiring surgical intervention
Respiratory failure without arrest
Pulmonary embolism requiring surgical intervention
Stroke
Vascular repair near the implant site or venous entry site
Pericardial effusion not requiring pericardiocentesis or su
DVT lower extremity, post-operative
Total events
Minor adverse events directly related to lead extraction
Thrombosis of implant vein resulting in medical intervent
Arrhythmia requiring cardioversion
Pulmonary embolism not requiring surgical intervention
Respiratory failure without arrest
Vascular repair near the implant site or venous entry site
Total events (among 8 patients)
Major adverse events directly related to lead extraction
Cardiac avulsion or tear requiring thoracotomy, pericardio
Vascular tear (including axillary artery tear) requiring thor
surgical repair
Bleeding requiring transfusion
Death secondary to another major complication (3 vascu
Hemothorax from any source requiring transfusion
Total events (among 20 patients)
Values are n (%).
DVT  deep vein thrombosis; RA  right atrium; RV  right ventricnfection or DRE were all independent predictors of all dause in-hospital mortality. The somewhat higher all-cause
n-hospital mortality of 1.86% reflects the complex comor-
id conditions of this patient population, especially DRE.
The original PLEXES (Pacing Lead Extraction With the
xcimer Sheath) trial (3), a randomized prospective clinical
rial, compared the first iteration of the 12-F SLS laser
heath to a nonlaser cohort in 301 subjects with 465 chronic
acemaker leads. The procedural success in the laser group
as 94% with an associated major complication rate of
.96% compared with 64% success rate with the use of only
ocking stylets and nonpowered telescoping sheaths. The
se of laser tools resulted in quicker lead extraction; 10.1 
1.5 min with versus 12.9  19.2 min without laser (p 
.04) (3). Subsequently, when the total initial experience of
aser lead extraction in the U.S. was reported by Byrd et al.
5) on 2,561 pacing and defibrillator leads from 1,684
atients at 89 sites, the procedural success rate was 90% with
major complication rate of 1.9% with an in-hospital death
ate of 0.8%. Only implant duration independently pre-
27 (1.86%)
17 (1.17%)
13 (0.90%)
sis, chest tube, or surgical repair 9 (0.62%)
ube, or surgical repair axillary artery tear 6 (0.41%)
4 (0.28%)
3 (0.21%)
2 (0.14%)
2 (0.14%)
2 (0.14%)
1 (0.07%)
1 (0.07%)
1 (0.07%)
intervention 1 (0.07%)
1 (0.07%)
90
3 (0.21%)
2 (0.14%)
1 (0.07%)
1 (0.07%)
1 (0.07%)
8
sis, chest tube, or surgical repair 9 (0.62%)
y, pericardiocentesis, chest tube, or 6 (0.41%)
4 (0.28%)
rs [2 SVC, 1 SVC/RA], 1 cardiac tear [RV]) 4 (0.28%)
1 (0.07%)
24
 superior vena cava.cente
hest t
ion
rgical
ion
cente
acotom
lar teaicted procedure failure and female sex was the only
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Laser Lead Extraction February 9, 2010:579–86ultivariate predictor of complications (5). In agreement
ith the study by Byrd et al. (5), we found that longer
mplantation duration was associated with procedural fail-
re. In contrast with Byrd et al. (5), we found no association
etween gender and adverse events directly related to lead
xtraction; instead BMI 25 kg/m2 (underweight and
ormal weight) also predicted procedure related MAE.
dditionally, in our study, clinical or procedural failure was
ssociated with low procedure volumes.
Device-related infections continue to be the most com-
on indication for extraction (2,3,6,7). Local infection at
he pocket site has a variety of presentations including
rosion, erythema, frank purulent discharge, or wound
ehiscence, which may be accompanied by pain. It is
mportant to recognize and treat these local manifestations
f infection promptly and effectively so as to prevent
estering indolent infections that may lead to bacteremia
emographic Characteristics: Procedural MAETable 5 Demographic Characteristics: Procedural MAE
MAE (n  20) p Value
Center size (LALE experience over 4-yr study period),
cases
60 6 (2.88%) 0.0532
60–130 8 (1.70%)
130 6 (0.78%)
Location
EP laboratory 12 (1.43%) 1.00
Operating room 8 (1.36%)
Anesthesia
General 9 (1.16%) 0.68
IV sedation 9 (1.58%)
Unknown 2 (1.89%)
Pre-operative arterial line
Present 17 (1.48%) —
Absent 0 (0%)
Unknown 3 (1.07%)
Sex
Men 13 (1.25%) 0.66
Women 7 (1.72%)
BMI, kg/m2
25 11 (2.6%) 0.0164
25 5 (0.7%)
Diabetes
Yes 4 (1.00%) 0.62
No 16 (1.55%)
Renal insufficiency, mg/dl
Cr 2.0 5 (3.11%) 0.05
Cr 2.0 13 (1.10%)
Duration of lead (surrogate: longest lead represents
each patient), yrs
0–5 4 (0.80%) 0.34
5–10 7 (1.67%)
10 6 (1.8%)
Age, yrs 64.5 21.4 0.78
alues are n (%).
BMI  body mass index; Cr  creatinine; EP  electrophysiology; IV  intravenous; LALE 
aser-assisted lead extraction; MAE  major adverse event.nd possible resultant endocarditis as these latter more lerious sequelae are associated with a higher mortality rate
6). In our study, although the in-hospital mortality conse-
uence of DRE was numerically larger, the less impressive
anifestations of pocket infection were statistically not
istinguishable from the DRE patients. Although there is
lear indication that the entire device system should be
emoved in the presence of systemic infection, there has
ontinued to be some controversy regarding localized pocket
nfection. The NASPE 2000 guidelines stated that it was
cceptable to remove the device and cut the exposed parts of
he leads. Such a strategy is proving to be unsuccessful and
uts the patient at risk of smoldering infection that could
pread and increase the patient’s risk of death (8).
In this study, nonpocket infections, which presented as
acteremia, lead, or valvular vegetations, and/or sepsis were
efined as device-related endocarditis. We elected to classify
his group of patients as having DRE because when there is
ersistent bacteremia, it is assumed that any intravascular
evice is seeded and therefore infected. About half of all
nfections were classified as DRE, and these patients were
lder and had a higher rate of diabetes and renal insuffi-
iency (defined as a creatinine2.0 mg/dl). Despite the fact
hat the clinical success and MAE rates were similar to
atients with no DRE, the risk ratio for all-cause in-
ospital mortality in this group of patients was 4.8 times
igher (4.3%). Patients with DRE and concomitant diabe-
es had a 4 times higher mortality risk (7.9%) and DRE plus
enal insufficiency yielded a 6.3 times higher mortality risk
12.4%). This is all compared to the mortality rate in
atients without DRE (patients with either pocket infec-
ions or not infected) of 0.9%.
The literature reports DRE represents 10% to 23% of all
evice infections (8–10). In this analysis, DRE represented
1% of device infections and is likely due to the broader
efinition employed in our study and the referral patterns of
ome study centers. This broader definition was chosen as
he clinical implications of endocarditis, bacteremia, and
epsis in the setting of a CIED are the same: each requires
omplete extraction of the CIED and prolonged antibiotic
herapy.
Mortality rates of DRE treated medically with antibiotics
lone are very high, as much as 66% in some series; this is
ompared with a strategy that employs device extraction
here mortality in the literature is reported to be 13% to
1% (11–14). In our study, the all-cause in-hospital mor-
ality rate for the DRE population was 4.3%, 1.7% for
ocket infection and 0.3% for all noninfected patients. This
mphasizes the seriousness of bacteremia and/or vegetations
n patients with a CIED system, but also the seriousness of
ocket infections. In such patients, it is imperative to extract
nd remove the pulse generator, the active and abandoned
eads, and debridement of the infected pocket tissue.
In agreement with previous studies, the presence of
onfunctional and abandoned leads was the second most
ommon indication for extraction (2,3,15). Extraction of
eads in noninfected patients is considered controversial by
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onfunctional leads may be abandoned rather than ex-
racted. As the duration of implant for devices and leads
ncreases along with an aging population, a large number of
eads become nonfunctional. These can either be extracted
t the time of another planned procedure such as an
pgrade, or be left to be extracted when there is no other
hoice, such as in the presence of infection. This may result
n a large number of leads in any 1 patient that over time
ay pose an increased risk of complications. Abandoned
eads may also serve as a nidus for lead-related endocarditis.
n patients with device implants of more than 6 months,
ndocarditis usually resulted from bacteremia from a remote
ource (16). Suga et al. (17) reported that up to half of all
bandoned pacemaker leads (611 of 1,207) in their cohort
ecame nonfunctional. They found that more abandoned
eads were associated with a greater number of complica-
ions (17). Silvetti and Drago (18) reported on abandoned
eads in young patients. Five and 10 years after lead
bandonment, 2 patients developed lead endocarditis of a
otal of 18 patients with abandoned leads. The investigators
oncluded that abandonment just postpones inevitable lead
xtraction (18). In this study, we found that the success rate
as high and the complication rate exceedingly low for the
emoval of nonfunctioning leads. Extraction after some
ears of abandonment may be more difficult and be associ-
ted with increased risk. In this study, there was a progres-
ive increase in procedural failure with prolonged implan-
ation duration. The cumulative rate was 0.75% at 5 years,
.93% at 10 years, 1.2% at 15 years, 2.4% at 20 years, and
0.9% at 25 years. Procedural failure was statistically in-
reased when leads were implanted for 10 years. Extrac-
ion of leads may also be needed to establish and retain
enous access if the target vein is occluded in a situation
hen there is a need for upgrade from a pacemaker (19). In
his study, extraction for this indication was also associated
ith a high success rate and low complication rate. When
onsidering extraction for a noninfection-related indication
t is very important to weigh the risks for a particular
Device-Related Endocarditis and Pocket InfectioTable 6 Device-Related Endocarditis and Po
DRE  P
n 825
Men (n  1,449) 618
Age, yrs (n  1,449) 67.
Ejection fraction 30% (n  1,449) 449
History of diabetes (n  1,449) 289
History of renal failure (n  1,347)
Cr 2.0 mg/dl 125
Cr 2.5 mg/dl 93
Clinical success (n  1,449) 810
Procedure-related MAE (n  1,449) 12
All-cause mortality (n  1,449) 25
Values are n (%) or mean  SD. *Odds ratio: 9.7.
Abbreviations as in Tables 2 and 5.atient, including operator experience, against the risk of wbandoning these leads. The decision to extract should be
ndividualized and discussed in detail with the patient and
amily.
It is at this point where the consideration of center laser
ead extraction experience is most important. Operator
xperience with laser lead extraction is important in deter-
ining clinical outcome. In this study, the small centers had
higher cumulative procedural MAE. A less experienced
enter (60 cases) was also associated with procedural and
linical failure. These findings are in agreement with pre-
ious studies demonstrating a significant learning curve for
his procedure (20). Therefore, centers should consider their
xtraction volume when deciding to perform this procedure
nd whether extractions should be referred to higher volume
enters.
tudy limitations. The major limitation of this study is
ts retrospective nature. Although this study is a consec-
tive series, patients who did not undergo laser-assisted
xtraction were not included. Therefore, there could have
een selection bias, but the bias was most likely to the
ost challenging clinical scenarios as laser-assisted ex-
raction is reserved for leads with ingrown tissue and
nability to be removed with traction only. It is possible
hat the high success rate and low complication rates in
his study are due to the very experienced centers and
perators in this study. However, in the community,
hese more challenging cases are usually referred to
enters experienced in LALE.
Despite this limitation, the study is still valuable because
t represents the current real-world experience with LALE.
ollow-up was limited in this study to hospital discharge or
eath. The study found a significant mortality in patients
ith DRE. A longer follow-up period would have been
aluable in determining the ultimate outcomes in this
atient population.
We only studied patients undergoing laser lead extrac-
ion. Other techniques are currently used. When compared
o only countertraction sheaths, powered tools are much
ore effective as the results of the PLEXES trial revealed
Infection
Infection Others p Value
%) 624 (43.1%) 0.0001
%) 423 (67.8%) 0.003
.6 57.6 18.3 0.0001
%) 397 (63.6%) 0.0005
%) 114 (18.3%) 0.0001
%) 36 (6.4%) 0.0001
%) 19 (3.4%) 0.0001
%) 606 (97.1%) 0.24
) 8 (1.3%) 0.96
) 2 (0.3%) 0.0001*ncket
ocket
(56.9
(74.9
8 14
(54.4
(35.0
(16.0
(11.9
(98.2
(1.5%
(3.0%hen this was compared with laser-powered sheaths (3).
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Laser Lead Extraction February 9, 2010:579–86lectrosurgical dissection sheaths that use radiofrequency
re also currently in use and achieve a much higher complete
xtraction rate than nonpowered countertraction sheaths,
3% versus 73%. The electrosurgical-powered sheaths also
esulted in less time needed for complete extraction 9.6 
.2 min versus 21  9 min (20).
A new Evolution Mechanical Dilator Sheath (Cook
edical, Bloomington, Indiana) with a stainless steel
laded rotating tip has been recently introduced and de-
cribed (21). However, the efficacy and safety has not been
tudied in a large patient population and has not been
ompared with standard tools. There have been no studies
omparing the different powered tools to each other.
onclusions
ransvenous laser-assisted lead extraction is highly success-
ul with a low procedural complication rate for a wide range
f indications. Device-related infection was the most com-
on indication for lead extraction and both DRE and
ocket infections carry a substantial in-hospital mortality
isk despite successful removal of the infected device and
eads. Therefore an increased emphasis must be placed on
echniques that reduce the potential for DRE. Indicators of
decreased clinical and procedural success include average
o small BMI, lead implantation duration of over 10 years,
nd extraction centers with small extraction volumes. The
ingle indicator of lead extraction associated complications
s an average or small BMI, whereas in-hospital mortality is
ncreased by a clinical history of pocket infection or DRE as
ell as diabetes and renal insufficiency.
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APPENDIX
or a list of the centers and cases per center,
lease see the online version of this article.
